Deals Shaping The Medical Industry (01/2012)
Executive Summary
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
UK Government Narcotics Advisors Recommend 0.05mg THC Limit For CBD Products
An advisory body to the UK government recommends a single-dose limit of 50 micrograms tetrahydrocannabinol (THC) for cannabidiol food products sold in the country. An analysis by Canna Consultants suggests this might translate in practice to today's widely assumed, although technically false, 0.2mg per retail unit limit.
Stada Expands Supply Network With Romanian Facility
Stada is investing nearly €50m in a Romanian supply-chain hub that it says will support future growth for the company, benefiting from its central European location. Meanwhile, the company has also struck medical cannabis deals with German insurers AOK and IKK.
Pharma R&D Legend Stoffels To Take Helm At Galapagos
The troubled Belgian biotech has pulled off a major coup in hiring Paul Stoffels, the architect of J&J's R&D successes over the last decade, as its new CEO.